PRNewsWire
31 Jul 2026, 21:34 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
FibroBiologics has dosed the first patients in a phase 1/2 clinical trial for its lead wound care candidate, CYWC628, targeting diabetic foot ulcers. — Transitioning from preclinical to clinical stage is a major value-inflection point for biotech companies.
+0.60The company expects to report interim results for the CYWC628 trial in the second half of 2026. — Provides a concrete timeline for a near-term catalyst that will determine the lead candidate's viability.
+0.40Which stocks this story touches
The company reported progress in its clinical trials, specifically dosing the first patients for its lead wound care candidate.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
58m ago
